Emerging Growth Trends Driving the Expansion of the Drug Repurposing Market

Exploring the Future of the Drug Repurposing Market
The drug repurposing sector is on track for significant expansion over the coming years. Experts forecast the market reaching a valuation of $58.33 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.2%. This upward trajectory is driven by several factors, including the integration of artificial intelligence (AI) and machine learning into drug repurposing, increased funding for biotech and pharmaceutical research, the broader capabilities of contract research organizations (CROs), a rising demand for cost-effective treatments, and supportive regulatory frameworks for repurposed drugs. Key trends anticipated during this period involve a stronger emphasis on phenotypic and target-based screening methods, greater adoption of structure-based drug repositioning, advances in identifying off-target activities, expanded use of repurposed drugs for rare and infectious diseases, and the shortening of drug development timelines by leveraging existing molecules.

Key Players Leading the Drug Repurposing Market
The drug repurposing market features several prominent companies shaping its landscape, including F. Hoffmann-La Roche Ltd, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., and BioXcel Therapeutics Inc. A notable recent development happened in July 2025 when Predictive Oncology Inc., a US-based company specializing in AI-driven drug discovery and repurposing, entered a $10 million share purchase agreement with YA II PN, Ltd. This partnership aims to accelerate the identification of new therapeutic indications for existing drugs and streamline oncology drug discovery by enhancing Predictive Oncology's AI platform. YA II PN, Ltd. is a US-based investment fund managed by Yorkville Advisors Global, LP, providing financial backing to innovative healthcare initiatives.

Download a free sample of the drug repurposing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Technological Advances Sparking Change in Drug Repurposing
Leading companies in the drug repurposing field are increasingly leveraging cutting-edge technologies such as AI-powered drug-protein interaction modeling to speed up the discovery of new uses for existing medications. This sophisticated approach uses vast datasets and machine learning to predict how drugs interact with various proteins throughout the human proteome, improving the precision and reliability of drug repositioning efforts. For example, Cosmos Health Inc., a US healthcare firm, launched Cloudscreen 2.0 in July 2025-an advanced AI platform designed to analyze drug-protein interactions on a much larger scale than previous systems. This next-generation tool integrates mutagenesis data and capabilities for studying disordered proteins, focusing on treating conditions like cancer, obesity, and diabetes. The platform's use of GPU-based cloud computing allows scalable data processing, making it a vital innovation for accelerating research pipelines across multiple therapeutic areas.

Diverse Segments Within the Drug Repurposing Market
The drug repurposing market is segmented across several dimensions to capture its full scope. These include:
1) Type: Disease-Centric, Target-Centric, and Drug-Centric repurposing approaches.
2) Drug Molecules: Divided into biologics and small molecules.
3) Therapeutic Areas: Covering oncology, neurology, infectious diseases, cardiovascular diseases, and autoimmune disorders.
4) Routes of Administration: Oral, intravenous, topical, inhalation, and intramuscular options.
5) End-Users: Pharmaceutical companies, research and academic institutions, and contract research organizations (CROs).

View the full drug repurposing market report:
https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Further subcategories provide even more granularity:
- Disease-Centric methods include phenotypic screening, epidemiological analysis, and clinical observation-based repurposing.
- Target-Centric approaches involve protein target modulation, pathway modulation, and biomarker-based targeting.
- Drug-Centric strategies focus on off-target activity identification, structure-based drug repositioning, and adverse effect-based repurposing.

Together, these segments outline the complex and evolving landscape of drug repurposing, highlighting the market's potential to revolutionize drug development and patient care.

Our 2026 market reports now offer broader strategic coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.